Canaccord Genuity Group Increases GH Research (NASDAQ:GHRS) Price Target to $31.00

GH Research (NASDAQ:GHRS) had its price objective increased by analysts at Canaccord Genuity Group from $30.00 to $31.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 156.62% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Monday, March 4th. JMP Securities reduced their target price on shares of GH Research from $50.00 to $39.00 and set a “market outperform” rating for the company in a report on Friday, March 1st.

GH Research Stock Performance

Shares of GHRS stock opened at $12.08 on Monday. GH Research has a 52-week low of $5.05 and a 52-week high of $14.64. The stock has a market cap of $628.52 million, a price-to-earnings ratio of -18.87 and a beta of 0.80. The firm’s 50-day moving average is $10.45 and its 200-day moving average is $8.04.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Sell-side analysts predict that GH Research will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GHRS. BVF Inc. IL boosted its position in shares of GH Research by 12.1% in the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after acquiring an additional 1,125,000 shares during the period. AdvisorShares Investments LLC raised its stake in GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after purchasing an additional 1,977 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in GH Research by 14.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock valued at $617,000 after purchasing an additional 13,579 shares during the period. RTW Investments LP grew its position in shares of GH Research by 53.4% during the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after purchasing an additional 1,158,172 shares in the last quarter. Finally, Lynx1 Capital Management LP increased its holdings in shares of GH Research by 13.8% during the third quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after purchasing an additional 133,804 shares during the period. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).